article thumbnail

Updated Evidence-Based Recommendations for Pneumococcal Conjugate Vaccines

Drug Topics

Panelists discuss how ACIP's decision to lower the pneumococcal conjugate vaccine age recommendation from 65 to 50 years was supported by evidence showing that 33-54% of adults aged 50-64 already had risk factors for vaccination, nearly 90% of those hospitalized with pneumococcal disease in this age group had at least one risk condition, mortality (..)

article thumbnail

Flu Vaccines Are a Go

Pharmacy Times

The shift away from thimerosal may increase the use of single-dose syringes, impacting vaccination practices in various healthcare settings. ACIP's recommendations are increasingly significant for pharmacies, influencing vaccination planning, billing, and patient care activities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RSV Vaccine Uptake Remains Low Among US Adults Aged 60 Years and Older

Pharmacy Times

Despite FDA-approved vaccines, only 16.4% of adults aged 60 and older were vaccinated by February 2025, indicating low uptake. Despite FDA-approved vaccines, only 16.4% of adults aged 60 and older were vaccinated by February 2025, indicating low uptake.

article thumbnail

From Pharmacy Counters to Classrooms: Building Confidence in Back-to-School Vaccinations

Pharmacy Times

Parental vaccine hesitancy, fueled by misinformation and logistical barriers, contributes to lower immunization rates and increased exemption rates. Parental vaccine hesitancy, fueled by misinformation and logistical barriers, contributes to lower immunization rates and increased exemption rates.

article thumbnail

V116 Well-Tolerated With Broad Immune Responses in Pneumococcal Vaccine-Naïve Older Adults

Pharmacy Times

The vaccine showed superior immune response for unique serotypes compared to PPSV23, with higher OPA titers. Insights from the Japanese study can inform global pneumococcal vaccination strategies for older adults at increased risk. 1 Older adults are at increased risk of invasive pneumococcal disease.

article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.

article thumbnail

COVID-19 Pandemic Reduced Gaps in Pneumococcal Vaccination in Medicare Enrollees, But Lowered Overall Uptake

Pharmacy Times

Increased awareness of infectious diseases during the pandemic may have improved vaccine uptake among Medicare enrollees, while service reductions and vaccine hesitancy affected Medicaid enrollees.